Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells

NCT06198296 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT06198296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06198296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using Interleukin-15 And -21 Armored Glypican-3-Specific Chimeric Antigen Receptor Expressing Autologous T Cells
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Recruiting
Start date
June 10, 2025
Completion date
February 1, 2043
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

embryonal sarcoma of liver, hepatoblastoma, hepatocellular carcinoma, liposarcoma, malignant rhabdoid tumor, rhabdomyosarcoma, wilms tumor, yolk sac tumor